Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Devyser Diagnostics

108.20 SEK

+0.19 %

Less than 1K followers

DVYSR

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+0.19 %
-12.74 %
-27.09 %
-5.58 %
-8.69 %
-12.03 %
+54.62 %
-
+21.57 %

Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.

Read more
Market cap
1.8B SEK
Turnover
819.17K SEK
Revenue
216.9M
EBIT %
-26.88 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/2
2026

Annual report '25

6/5
2026

General meeting '26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Press release12/4/2025, 8:30 AM

Health Canada grants IVD approval to Devyser’s NGS-based chimerism test, the first of its kind in Canada

Devyser Diagnostics
Regulatory press release11/28/2025, 2:00 PM

Devyser stärker sin närvaro på den amerikanska marknaden med CMS-prissättning för PrenatalDetect RHD-test

Devyser Diagnostics
Regulatory press release11/28/2025, 2:00 PM

Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test

Devyser Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/25/2025, 9:00 AM

Devyser advances U.S. clinical strategy with first patient enrolled in Devyser Accept cfDNA study

Devyser Diagnostics
Press release11/7/2025, 7:41 AM

Redeye: Devyser Diagnostics (Q3 Review) - Exaggerated reaction, strong Q4 ahead

Devyser Diagnostics
Devyser Diagnostics, Audiocast, Q3'25
Webcast11/5/2025, 8:00 AM

Devyser Diagnostics, Audiocast, Q3'25

Devyser Diagnostics
Regulatory press release11/5/2025, 6:30 AM

Devyser Diagnostics AB publicerar kvartalsrapport för juli till september 2025

Devyser Diagnostics
Regulatory press release11/5/2025, 6:30 AM

Devyser Diagnostics AB publishes quarterly report for the period July to September 2025

Devyser Diagnostics
Press release11/4/2025, 8:30 AM

Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics

Devyser Diagnostics
Press release10/29/2025, 8:30 AM

Invitation to presentation of Devyser’s Q3 2025 Interim Report

Devyser Diagnostics
Press release10/29/2025, 8:30 AM

Inbjudan till presentation av Devysers delårsrapport Q3 2025

Devyser Diagnostics
Regulatory press release9/22/2025, 11:15 AM

Kommuniké från extra bolagsstämma i Devyser Diagnostics AB (publ) den 22 september 2025

Devyser Diagnostics
Regulatory press release9/22/2025, 11:15 AM

Bulletin from an Extraordinary General Meeting in Devyser Diagnostics AB (publ) held on 22 September 2025

Devyser Diagnostics
Regulatory press release8/28/2025, 2:45 PM

Kallelse till extra bolagsstämma i Devyser Diagnostics AB (publ)

Devyser Diagnostics
Press release7/23/2025, 9:38 AM

Redeye: Devyser Q2 - Profitable from here on

Devyser Diagnostics
Devyser Diagnostics, Audiocast, Q2'25
Webcast7/22/2025, 7:00 AM

Devyser Diagnostics, Audiocast, Q2'25

Devyser Diagnostics
Regulatory press release7/22/2025, 5:30 AM

Devyser Diagnostics AB publicerar kvartalsrapport för april till juni 2025

Devyser Diagnostics
Regulatory press release7/22/2025, 5:30 AM

Devyser Diagnostics AB publishes quarterly report for the period April to June 2025

Devyser Diagnostics
Press release7/14/2025, 7:30 AM

Inbjudan till presentation av Devysers delårsrapport Q2 2025

Devyser Diagnostics
Press release7/14/2025, 7:30 AM

Invitation to presentation of Devyser’s Q2 2025 Interim Report

Devyser Diagnostics
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.